Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 3
1975 5
1976 6
1977 9
1979 3
1980 2
1981 3
1982 2
1983 8
1984 8
1985 13
1986 8
1987 16
1988 11
1989 16
1990 18
1991 8
1992 8
1993 11
1994 9
1995 6
1996 8
1997 7
1998 4
1999 7
2000 3
2001 7
2002 2
2003 5
2004 3
2005 3
2006 6
2007 5
2008 4
2009 7
2010 6
2011 10
2012 8
2013 6
2014 3
2015 4
2016 8
2017 9
2018 10
2019 7
2020 8
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

318 results
Results by year
Filters applied: . Clear all
Page 1
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Yu AL, et al. Among authors: sondel pm. N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123. N Engl J Med. 2010. PMID: 20879881 Free PMC article. Clinical Trial.
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Among authors: sondel pm. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Mody R, et al. Among authors: sondel pm. J Clin Oncol. 2020 Jul 1;38(19):2160-2169. doi: 10.1200/JCO.20.00203. Epub 2020 Apr 28. J Clin Oncol. 2020. PMID: 32343642 Clinical Trial.
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Ascierto PA, et al. Among authors: sondel pm. J Immunother Cancer. 2020 Apr;8(1):e000878. doi: 10.1136/jitc-2020-000878. J Immunother Cancer. 2020. PMID: 32300051 Free PMC article. No abstract available.
Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
Voeller J, Erbe AK, Slowinski J, Rasmussen K, Carlson PM, Hoefges A, VandenHeuvel S, Stuckwisch A, Wang X, Gillies SD, Patel RB, Farrel A, Rokita JL, Maris J, Hank JA, Morris ZS, Rakhmilevich AL, Sondel PM. Voeller J, et al. Among authors: sondel pm. J Immunother Cancer. 2019 Dec 6;7(1):344. doi: 10.1186/s40425-019-0823-6. J Immunother Cancer. 2019. PMID: 31810498 Free PMC article.
Graft-versus-leukemia reactions after bone marrow transplantation.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, et al. Horowitz MM, et al. Among authors: sondel pm. Blood. 1990 Feb 1;75(3):555-62. Blood. 1990. PMID: 2297567 Free article.
318 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page